Back to search

University of Sheffield

Development of intronless expression systems for biomanufacturing

Abstract

dc:description.abstract

Biotherapeutic molecules, such as monoclonal antibodies (mAbs), represent a sizeable proportion of newly approved therapeutic’s available for treatment of disease. Reducing the production costs of these therapeutics, usually produced in massive quantities from Chinese Hamster Ovary (CHO) cells, remains a key focus of the pharmaceutical industry. The presence of introns in the expression cassettes of mAbs are an effective way of achieving high therapeutic protein expression levels. However, frequent mis-splicing events lead to the formation of aberrant protein structures, lowering the yield of the therapeutic protein and requiring filtration from the final product. This leads to increased production costs resulting in increased cost for the consumer and thus lowering the availability of the drug. To counteract this problem, in this project we set out to develop expression systems with increased therapeutic protein yield from an intronless expression cassette. We demonstrate that improving the GC content of an intronless sequence improves protein expression through improved mRNA export via interactions with the mRNA export factor ALYREF. We go on to show that inclusion of RNA-binding protein (RBPs) recruitment motifs for SRSF1/SRSF7 and SF3b1 into the intronless sequence improves therapeutic protein expression, showing that mRNA processing is a good expression stage to target to in this process. We further demonstrate the potential for both GC content and RBP recruitment motifs to work in tandem to improve therapeutic protein expression and provide evidence that these improvements work in an industrial setting. Finally, we investigate the role of the HUSH complex in mediated silencing of intronless expression sequences, showing that this HUSH complex may not play a key role in reducing protein expression levels from intronless sequences. Additionally, we show the potential of HNRNPU silencing as a method of improving therapeutic production, but further development of this system is required to alleviate certain drawbacks associated with HNRNPU silencing.

Degree

thesis:*
Name dc:type.qualificationname
Ph.D
Level dc:type.qualificationlevel
doctoral
Grantor dc:publisher.institution
University of Sheffield
Year dc:date.issued
2024

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Zilate, Joshua
Advisor dc:contributor.advisor
  • Wilson, Stuart

Rights

Language dc:language.dcterms_iso639_2
eng

Chain of custody

source
Harvested from
White Rose University Consortium
Base URL
etheses.whiterose.ac.uk/cgi/oai2
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
related terms
citation

Zilate, Joshua. Development of intronless expression systems for biomanufacturing. doctoral thesis, University of Sheffield, 2024.